Taltz and Lung disorder - a phase IV clinical study of FDA data

Summary:

Lung disorder is reported as a side effect among people who take Taltz (ixekizumab), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Humira, and have Psoriasis.

The phase IV clinical study analyzes which people have Lung disorder when taking Taltz. It is created by eHealthMe based on reports of 29,745 people who have side effects when taking Taltz from the FDA, and is updated regularly.

What is Taltz?

Taltz has active ingredients of ixekizumab. eHealthMe is studying from 29,777 Taltz users. Check the latest studies of Taltz.

What is Lung disorder?

Lung disorder (lung disease) is found to be associated with 1,804 drugs and 1,786 conditions by eHealthMe. Check the latest studies of Lung disorder.

On Jul, 23, 2026

29,745 people reported to have side effects when taking Taltz.
Among them, 18 people (0.06%) have Lung disorder.

Among these 18 people:

How long have people been on Taltz when they have Lung disorder? *

What is the gender of people who have Lung disorder when taking Taltz? *

female: 61.11 %
male: 38.89 %

What is the age of people who have Lung disorder when taking Taltz? *

What are other drugs people take besides Taltz? *

What are other side effects people have besides Lung disorder? *

Oral Candidiasis (fungal infection of mouth): 2 people, 11.11%
Cough: 2 people, 11.11%
Sleep Disorder: 2 people, 11.11%
Weakness: 1 person, 5.56%
Dyspnea (difficult or laboured breathing): 1 person, 5.56%
Acute Upper Airway Obstruction (blockage occurs in the upper airway): 1 person, 5.56%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 5.56%
Bacterial Infection: 1 person, 5.56%
Blood Glucose Increased: 1 person, 5.56%
Cardiac Disorder: 1 person, 5.56%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 10 people, 55.56%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 6 people, 33.33%
Diabetes: 2 people, 11.11%
Iron Deficiency Anaemia: 1 person, 5.56%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 5.56%
Depression: 1 person, 5.56%
Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 1 person, 5.56%
Ankylosing Spondylitis (type of arthritis affecting the spine): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Taltz and have Lung disorder?

- Check whether Lung disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Taltz:

Taltz (29,777 reports)

Lung disorder treatments and more:

Lung disorder (66,567 reports)

Browse all side effects of Taltz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lung disorder:

Lung disorder (1,804 drugs)

Browse all the conditions that are associated with Lung disorder:

Lung disorder (1,786 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ixekizumab (the active ingredients of Taltz) and Taltz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.